145 related articles for article (PubMed ID: 8915605)
1. Molecular mechanisms of fibrillogenesis and the protective role of amyloid P component: two possible avenues for therapy.
Pepys MB; Tennent GA; Booth DR; Bellotti V; Lovat LB; Tan SY; Persey MR; Hutchinson WL; Booth SE; Madhoo S; Soutar AK; Hawkins PN; Van Zyl-Smit R; Campistol JM; Fraser PE; Radford SE; Robinson CV; Sunde M; Serpell LC; Blake CC
Ciba Found Symp; 1996; 199():73-81; discussion 81-9. PubMed ID: 8915605
[TBL] [Abstract][Full Text] [Related]
2. Serum Amyloid P Component Ameliorates Neurological Damage Caused by Expressing a Lysozyme Variant in the Central Nervous System of Drosophila melanogaster.
Helmfors L; Bergkvist L; Brorsson AC
PLoS One; 2016; 11(7):e0159294. PubMed ID: 27428539
[TBL] [Abstract][Full Text] [Related]
3. Serum amyloid P component promotes formation of distinct aggregated lysozyme morphologies and reduces toxicity in Drosophila flies expressing F57I lysozyme.
Bergkvist L; Richards DR; Bernardo-Gancedo A; Kumita JR; Nilsson PR; Brorsson AC
PLoS One; 2020; 15(1):e0227227. PubMed ID: 31978114
[TBL] [Abstract][Full Text] [Related]
4. Pathogenesis, diagnosis and treatment of systemic amyloidosis.
Pepys MB
Philos Trans R Soc Lond B Biol Sci; 2001 Feb; 356(1406):203-10; discussion 210-1. PubMed ID: 11260801
[TBL] [Abstract][Full Text] [Related]
5. Ageing and amyloid fibrillogenesis: lessons from apolipoprotein AI, transthyretin and islet amyloid polypeptide.
Westermark P; Sletten K; Johnson KH
Ciba Found Symp; 1996; 199():205-18; discussion 218-22. PubMed ID: 8915612
[TBL] [Abstract][Full Text] [Related]
6. Hereditary renal amyloidosis associated with variant lysozyme in a large English family.
Gillmore JD; Booth DR; Madhoo S; Pepys MB; Hawkins PN
Nephrol Dial Transplant; 1999 Nov; 14(11):2639-44. PubMed ID: 10534505
[TBL] [Abstract][Full Text] [Related]
7. Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis.
Booth DR; Sunde M; Bellotti V; Robinson CV; Hutchinson WL; Fraser PE; Hawkins PN; Dobson CM; Radford SE; Blake CC; Pepys MB
Nature; 1997 Feb; 385(6619):787-93. PubMed ID: 9039909
[TBL] [Abstract][Full Text] [Related]
8. Metabolism of amyloid proteins.
Benson MD; Kluve-Beckerman B; Liepnieks JJ; Murrell JR; Hanes D; Uemichi T
Ciba Found Symp; 1996; 199():104-13; discussion 113-8. PubMed ID: 8915606
[TBL] [Abstract][Full Text] [Related]
9. Amyloid fibril formation and seeding by wild-type human lysozyme and its disease-related mutational variants.
Morozova-Roche LA; Zurdo J; Spencer A; Noppe W; Receveur V; Archer DB; Joniau M; Dobson CM
J Struct Biol; 2000 Jun; 130(2-3):339-51. PubMed ID: 10940237
[TBL] [Abstract][Full Text] [Related]
10. Amyloidosis: new strategies for treatment.
Hirschfield GM; Hawkins PN
Int J Biochem Cell Biol; 2003 Dec; 35(12):1608-13. PubMed ID: 12962700
[TBL] [Abstract][Full Text] [Related]
11. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis.
Pepys MB; Herbert J; Hutchinson WL; Tennent GA; Lachmann HJ; Gallimore JR; Lovat LB; Bartfai T; Alanine A; Hertel C; Hoffmann T; Jakob-Roetne R; Norcross RD; Kemp JA; Yamamura K; Suzuki M; Taylor GW; Murray S; Thompson D; Purvis A; Kolstoe S; Wood SP; Hawkins PN
Nature; 2002 May; 417(6886):254-9. PubMed ID: 12015594
[TBL] [Abstract][Full Text] [Related]
12. Homozygous serum amyloid P component-deficiency does not enhance regression of AA amyloid deposits.
Usui I; Kawano H; Ito S; Hamada Y; Ishihara T; Maeda S
Amyloid; 2001 Jun; 8(2):101-4. PubMed ID: 11409030
[TBL] [Abstract][Full Text] [Related]
13. Hereditary hepatic and systemic amyloidosis caused by a new deletion/insertion mutation in the apolipoprotein AI gene.
Booth DR; Tan SY; Booth SE; Tennent GA; Hutchinson WL; Hsuan JJ; Totty NF; Truong O; Soutar AK; Hawkins PN; Bruguera M; Caballería J; Solé M; Campistol JM; Pepys MB
J Clin Invest; 1996 Jun; 97(12):2714-21. PubMed ID: 8675681
[TBL] [Abstract][Full Text] [Related]
14. Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis.
Tennent GA; Lovat LB; Pepys MB
Proc Natl Acad Sci U S A; 1995 May; 92(10):4299-303. PubMed ID: 7753801
[TBL] [Abstract][Full Text] [Related]
15. Amyloidosis: a clinico-pathophysiological synopsis.
Hirschfield GM
Semin Cell Dev Biol; 2004 Feb; 15(1):39-44. PubMed ID: 15036205
[TBL] [Abstract][Full Text] [Related]
16. The extreme N-terminal region of human apolipoprotein A-I has a strong propensity to form amyloid fibrils.
Adachi E; Kosaka A; Tsuji K; Mizuguchi C; Kawashima H; Shigenaga A; Nagao K; Akaji K; Otaka A; Saito H
FEBS Lett; 2014 Jan; 588(3):389-94. PubMed ID: 24316228
[TBL] [Abstract][Full Text] [Related]
17. Structural diversity of ex vivo amyloid fibrils studied by cryo-electron microscopy.
Jiménez JL; Tennent G; Pepys M; Saibil HR
J Mol Biol; 2001 Aug; 311(2):241-7. PubMed ID: 11478857
[TBL] [Abstract][Full Text] [Related]
18. Amyloidosis.
Tan SY; Pepys MB
Histopathology; 1994 Nov; 25(5):403-14. PubMed ID: 7868080
[TBL] [Abstract][Full Text] [Related]
19. Mechanistic studies of the folding of human lysozyme and the origin of amyloidogenic behavior in its disease-related variants.
Canet D; Sunde M; Last AM; Miranker A; Spencer A; Robinson CV; Dobson CM
Biochemistry; 1999 May; 38(20):6419-27. PubMed ID: 10350460
[TBL] [Abstract][Full Text] [Related]
20. Human lysozyme gene mutations cause hereditary systemic amyloidosis.
Pepys MB; Hawkins PN; Booth DR; Vigushin DM; Tennent GA; Soutar AK; Totty N; Nguyen O; Blake CC; Terry CJ
Nature; 1993 Apr; 362(6420):553-7. PubMed ID: 8464497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
